ACS CAN Comments on FDA Draft Guidance on Collection of Race and Ethnicity Data in Clinical Trials

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for Food and Drug Administration-Regulated Medical Products.